Skip to content

Effects of Transversus Abdominis Plane Block on Recovery Quality and Maternal-Neonatal Outcomes After Cesarean Delivery

Effects of Transversus Abdominis Plane Block on Recovery Quality and Maternal-Neonatal Outcomes After Cesarean Delivery

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07478692
Enrollment
83
Registered
2026-03-17
Start date
2025-06-01
Completion date
2025-10-31
Last updated
2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain After Cesarean Section

Brief summary

ltrasound-guided transversus abdominis plane (TAP) block is an emerging local anesthesia technique that effectively alleviates postoperative pain by injecting anesthetic drugs around the nerves in the abdominal wall. Compared with traditional analgesic methods, TAP blockade may have better analgesic effects and fewer side effects. However, current research on the application of TAP blockade after cesarean section is still limited. Therefore, this study will systematically evaluate its actual effectiveness in pain management after cesarean section through a prospective randomized controlled trial

Interventions

DRUGThe TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg)

the control group received only the same formula intravenous analgesia pump

Sponsors

Qing Yuan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 20-40 years, in good general health * ASA physical status I-II * Singleton, term (37-41 weeks) pregnancy with normal fetal development * Planned for elective cesarean section, no labor

Exclusion criteria

* Pregnancy complications (e.g., severe preeclampsia, gestational diabetes, placental abruption) * Major organ dysfunction (heart, liver, kidney) or psychiatric history * Allergy to local anesthetics or any study drugs * Prior abdominal surgery or infection that may affect block efficacy * Coagulation disorders or current anticoagulant use * Refusal to participate or inability to comply with follow-up

Design outcomes

Primary

MeasureTime frameDescription
VAS pain scores (0-10 scale, where 0 = no pain and 10 = unbearable severe pain) at rest and during activity ( Time to first rescue analgesia requirement and number of patients and total dosage of flurbiprofen axetil used within 48 hours postoperatively;5 monthsVAS pain scores (0-10 scale, where 0 = no pain and 10 = unbearable severe pain) at rest and during activity (coughing or turning) at 2, 6, 12, 24, and 48 hours postoperatively were recorded by anesthesiologists not involved in this study.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026